Washington, DC (November 19, 2024) – Today, the Pharmaceutical Printed Literature Association (PPLA) released new consumer survey data showing that Rx drug consumers overwhelmingly want cognitively-backed and printed patient medication information (PMI). When presented with the Food and Drug Administration’s (FDA) proposed formatting and enhanced, cognitively-researched design, a survey of more than 500 Rx consumers revealed:
- 93% of survey respondents said enhanced, cognitively-researched PMI design was easier to understand than the FDA’s PMI
- 89% of survey respondents said they would prefer to keep the demonstrably effective enhanced PMI over the FDA’s
- 90% of respondents said if they were caregiving for a loved one, they’d prefer the enhanced PMI design over the FDA’s
- 64% of respondents said they’d have difficulty accessing PMI if it’s distributed electronically instead of print
Earlier this year when PPLA met with the FDA to share their concerns with a proposed rule that standardizes PMI, the FDA asked for more information on consumer preferences. After the meeting, PPLA conducted a survey of Rx consumers and shared the results with the FDA as they continue to consider the rule.
“PPLA and FDA share a common goal of PMI; to improve public health by providing patients with clear, concise, accessible, and useful written prescription drug product information delivered in a consistent and easily understood format to help patients use their prescription drug products safely and effectively,” PPLA wrote in a letter to the FDA sharing the data. “PPLA stands ready to work with FDA to achieve Patient Medication Information with an optimal standardized format and FDA-approved content that’s demonstrably effective, manufacturer printed, and distributed with all outpatient prescriptions.”
The Pharmaceutical Printed Literature Association
Chartered in 2001, the PPLA serves as the voice for our members, advocating for patient safety and risk communication by fighting to keep information on paper and readily accessible for patients and caregivers. This information helps drive the patient involvement model of health care, helping patients get the maximum benefits from the powerful drugs they take while minimizing risk.
For more information about PPLA, click here.